MODIFICATION
A -- NIAID Clinical Proteomics Centers for Infectious Disease and Biodefense
- Notice Date
- 7/19/2007
- Notice Type
- Modification
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions 6700 B Rockledge Room 3214 MSC7612, Bethesda, MD, 20892-7612, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- RFP-NIH-NIAID-DMID-08-18
- Response Due
- 11/15/2007
- Archive Date
- 11/30/2007
- Point of Contact
- Robert Singman, Contracting Officer, Phone 301-451-2607, Fax 301-480-4675, - Sharon Kraft, Branch Chief, Phone 301-496-0195, Fax 301-480-4675,
- E-Mail Address
-
RSingman@niaid.nih.gov, SKraft@niaid.niaid.nih.gov
- Description
- Introduction<br/> <br/> The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID), has a requirement for development of clinical proteomic biomarkers, resources and reagents that will enable clinical researchers to exploit the potential of applied proteomics to advance research related to clinically important fundamental problems in infectious diseases and biodefense.<br/> <br/> Description<br/> <br/> DMID requires the Clinical Proteomics Centers for Infectious Diseases and Biodefense to discover, qualify, and verify candidate protein biomarkers to be made widely available to the scientific community for use as reagents for further development. These candidate biomarkers are required to have the potential to be used clinically to improve detection and diagnosis, and to monitor therapeutic and vaccine responses and susceptibility to infection for diseases caused by NIAID Category A-C biodefense and emerging/re-emerging infectious disease pathogens (http://www3.niaid.nih.gov/biodefense/bandc_priority.htm). The Centers will be required to provide established high throughput, state-of-the-art proteomics facilities as a resource to NIAID and as a service to the broad scientific community for the conduct of clinical proteomics research projects proposed in collaboration with clinical infectious disease researchers to identify candidate protein biomarkers. DMID requires the Centers ensure a sustained source of well-characterized human clinical samples for clinical proteomics research projects to be conducted by the Center, and obtain well-characterized human clinical samples from cases and controls necessary to conduct clinical proteomics research projects. It is anticipated that one or more cost reimbursement, completion type contracts will be awarded for a five-year period of performance beginning on or about 8/1/2009. It is estimated that the provision of FTEs will be approximately as follows: 10.45 FTEs. Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about August 2, 2007. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. See Government-Wide Numbered Note 26.<br/>
- Place of Performance
- Address: Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, Office of Acquisitions, Attention: Robert J. Singman, Contract Specialist, 6700-B Rockledge Drive, Room 3214,
- Zip Code: 20892-7612
- Country: UNITED STATES
- Zip Code: 20892-7612
- Record
- SN01346657-W 20070721/070720001038 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |